Insider Selling: Sight Sciences (NASDAQ:SGHT) CEO Sells 25,356 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 25,356 shares of Sight Sciences stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $7.43, for a total transaction of $188,395.08. Following the completion of the sale, the chief executive officer owned 5,937,146 shares of the company’s stock, valued at approximately $44,112,994.78. The trade was a 0.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Paul Badawi also recently made the following trade(s):

• On Tuesday, January 6th, Paul Badawi sold 11,870 shares of Sight Sciences stock. The stock was sold at an average price of $7.48, for a total value of $88,787.60.

Sight Sciences Price Performance

Shares of NASDAQ SGHT traded down $0.24 during mid-day trading on Tuesday, reaching $7.47. The company had a trading volume of 197,717 shares, compared to its average volume of 290,394. The firm has a market cap of $394.94 million, a price-to-earnings ratio of -8.30 and a beta of 2.42. The business’s 50-day simple moving average is $7.52 and its 200 day simple moving average is $5.13. Sight Sciences, Inc. has a one year low of $2.03 and a one year high of $9.24. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.93 and a current ratio of 9.60.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Wednesday, September 8th. The company reported ($0.81) earnings per share (EPS) for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.The firm had revenue of $12.54 million for the quarter. On average, research analysts predict that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. UBS Group upped their target price on Sight Sciences from $7.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, December 23rd. Lake Street Capital boosted their price target on Sight Sciences from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, October 21st. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research report on Monday, December 29th. Piper Sandler set a $9.00 target price on Sight Sciences in a research report on Monday. Finally, Citigroup boosted their target price on Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $8.30.

Institutional Investors Weigh In On Sight Sciences

Several hedge funds have recently modified their holdings of the company. Alliancebernstein L.P. grew its position in Sight Sciences by 5.5% during the 3rd quarter. Alliancebernstein L.P. now owns 34,380 shares of the company’s stock worth $118,000 after acquiring an additional 1,800 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after purchasing an additional 2,875 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Sight Sciences by 1.0% during the third quarter. Dimensional Fund Advisors LP now owns 303,634 shares of the company’s stock worth $1,045,000 after purchasing an additional 3,051 shares during the last quarter. CWM LLC increased its stake in shares of Sight Sciences by 70.2% in the second quarter. CWM LLC now owns 7,607 shares of the company’s stock valued at $31,000 after buying an additional 3,137 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in Sight Sciences by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock valued at $26,000 after buying an additional 3,785 shares during the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

More Sight Sciences News

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight (from Neutral), a buy-side analyst upgrade that can attract investor interest and buying momentum. Piper Sandler upgrade
• Neutral Sentiment: Despite recent sales, insiders still hold large positions — CEO Paul Badawi (~5.9M shares) and CTO David Badawi (~1.9M shares) retain substantial ownership, which can indicate alignment with long-term value even as they trim stakes. Insider ownership filing
• Negative Sentiment: Clustered insider selling by executives — CEO Paul Badawi, CTO David Badawi, CFO James Rodberg, EVP Brenton Taylor and insider Jeremy Hayden — over Jan. 2–6. Combined disclosed sales total roughly $0.48M across these transactions; each sale was a small percentage (<1%) of the seller’s holdings but the concentrated timing can create downward pressure on the stock. See CEO / executive filings. CEO sale filing CTO sale filing Other insider filings

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.